v3.25.2
Segment Reporting
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Reporting

Note 12. Segment Reporting

The Company has one reportable segment relating to which is the business of extending healthy human life by targeting molecular causes of aging.

The Company’s CODM is its chief executive officer. When evaluating the Company's financial performance, the CODM reviews total operating expenses and expense by function to make decisions on a company-wide basis.

As a single reportable segment entity, the determined measure of profit or loss is the Company’s consolidated net income (loss). Consolidated asset information for the Company’s single reportable segment is presented in the Company’s consolidated balance sheets.

The table below is a summary of the segment net loss, including significant segment expenses:

 

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Collaboration revenue

 

$

2,412

 

 

$

—

 

 

$

3,863

 

 

$

—

 

Segment expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Direct program costs

 

 

13,955

 

 

 

4,682

 

 

 

18,584

 

 

 

9,293

 

Indirect research and development expenses

 

 

5,889

 

 

 

5,789

 

 

 

12,369

 

 

 

10,499

 

General and administrative

 

 

7,339

 

 

 

4,798

 

 

 

14,127

 

 

 

8,290

 

Total operating and segment expenses

 

$

27,183

 

 

$

15,269

 

 

$

45,080

 

 

$

28,082

 

Loss from operations

 

$

(24,771

)

 

$

(15,269

)

 

$

(41,217

)

 

$

(28,082

)

Total other income (expense), net

 

 

3,208

 

 

 

1,688

 

 

 

6,726

 

 

 

1,509

 

Segment and consolidated net loss

 

$

(21,563

)

 

$

(13,581

)

 

$

(34,491

)

 

$

(26,573

)